The Role of Transanal Tube Drainage as A Mean of Prevention of Anastomotic Leakage Anastomotic Leakage
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03325361 |
|
Recruitment Status : Unknown
Verified October 2017 by Pierpaolo Sileri, University of Rome Tor Vergata.
Recruitment status was: Recruiting
First Posted : October 30, 2017
Last Update Posted : October 30, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Rectal Cancer Rectal Neoplasms Anastomotic Leak | Other: Tube drain insertion | Not Applicable |
Patients who underwent low or ultralow anterior resection for rectal cancer were enrolled between 01/2015 and 06/2017. A de-Pezzer catheter was placed transanally after the creation of the anastomosis, secured to the buttocks, and connected to a urine bag to allow monitoring the amount and the color of the drainage. The catheter was removed on the 3rd day postoperative if the volume collected was insignificant.
Patients were followed-up on the ward and then in the outpatient's department at two weeks, and one month postoperative. Patients who were suspected to have AL underwent CT with rectal contrast to assess the integrity of the anastomosis. The primary outcome was the incidence of AL. We adopted the definition published by the International Study Group of Rectal Cancer.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 100 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Prevention |
| Official Title: | The Role of Transanal Tube Drainage as A Mean of Prevention of Anastomotic Leakage |
| Estimated Study Start Date : | October 2017 |
| Estimated Primary Completion Date : | December 2017 |
| Estimated Study Completion Date : | June 2018 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: TD |
Other: Tube drain insertion
A de-Pezzer catheter was placed transanally after the creation of the anastomosis, secured to the buttocks, and connected to a urine bag to allow monitoring the amount and the color of the drainage. The catheter was removed on the 3rd day postoperative if the volume collected was insignificant. |
| No Intervention: NTD |
- Anastomotic leakage [ Time Frame: 30 days ]Prevention
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Low or ultralow anterior resection with primary anastomosis for biopsy-proven primary rectal cancer
Exclusion Criteria:
- No anastomosis
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03325361
| Contact: Pierpaolo Sileri, PhD | 3209353441 | piersileri@yahoo.com | |
| Contact: Mostafa Shalaby, PhD | shalaby-mostafa@hotmail.com |
| Italy | |
| Policlinico Tor Vergata Hospital | Recruiting |
| Rome, RM, Italy, 00133 | |
| Contact: Pierpaolo Sileri 3209353441 | |
| Responsible Party: | Pierpaolo Sileri, Professor, University of Rome Tor Vergata |
| ClinicalTrials.gov Identifier: | NCT03325361 |
| Other Study ID Numbers: |
Transanal Tube Drainage |
| First Posted: | October 30, 2017 Key Record Dates |
| Last Update Posted: | October 30, 2017 |
| Last Verified: | October 2017 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Rectal Neoplasms Anastomotic Leak Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site |
Neoplasms Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Rectal Diseases Postoperative Complications Pathologic Processes |

